Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.68 |
| ▸ | PPARG | P37231 | 4/20 | 0.56 |
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824562 | 1.00 | MAOA (0.71) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| SCHEMBL6231179 | 0.89 | PPARG (0.56) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| SCHEMBL6231177 | 0.89 | PPARG (0.56) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| SCHEMBL17201747 | 0.87 | MAOA (0.57) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| SCHEMBL13824956 | 0.87 | MAOA (0.57) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| SCHEMBL28185918 | 0.87 | MAOA (0.73) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| Arachidin-2 SCHEMBL31544968 | 0.83 | MAOA (1.00) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| Arachidin-2 SCHEMBL6232566 | 0.83 | MAOA (1.00) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| Arachidin-2 SCHEMBL4742876 | 0.83 | MAOA (1.00) | MAOAMAOBCYP19A1ALOX5PTGS2 | |
| SCHEMBL13970532 | 0.81 | CYP19A1 (1.00) | MAOAMAOBCYP19A1ALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634375-B2 | Prenylated hydroxystilbenes | Kynan Duke IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220380285-A1 | PRENYLATED HYDROXYSTILBENES | Kynan Duke IP, LLC (US) | 2022-12-01 | — | — | US | disclosed |
| US-11352310-B2 | Prenylated hydroxystilbenes | Kynan Duke IP, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200331833-A1 | PRENYLATED HYDROXYSTILBENES | THE UNIVERSITY OF SYDNEY (AU) | 2020-10-22 | — | — | US | disclosed |
| US-10696615-B2 | Prenylated hydroxystilbenes | THE UNIVERSITY OF SYDNEY (AU) | 2020-06-30 | — | — | US | disclosed |
| US-20190194105-A1 | PRENYLATED HYDROXYSTILBENES | THE UNIVERSITY OF SYDNEY (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10196335-B2 | Prenylated hydroxystilbenes | THE UNIVERSITY OF SYDNEY (AU) | 2019-02-05 | — | — | US | disclosed |
| US-20150307429-A1 | PRENYLATED HYDROXYSTILBENES | Kynan Duke IP, LLC | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196335-B2 | Prenylated hydroxystilbenes | HMGB2, CYP51A1, CYP8B1 | MAOA 4580/4885MAOB 4116/4885CYP19A1 212/4885 |
| US-20200331833-A1 | PRENYLATED HYDROXYSTILBENES | HSD11B1, HSD3B1, CYP8B1 | MAOA 3218/4885MAOB 1156/4885CYP19A1 64/4885 |
| US-20220380285-A1 | PRENYLATED HYDROXYSTILBENES | HSD11B1, HSD3B1, CYP8B1 | MAOA 3218/4885MAOB 1156/4885CYP19A1 64/4885 |
| US-20150307429-A1 | PRENYLATED HYDROXYSTILBENES | HMGB2, CYP51A1, CYP8B1 | MAOA 4580/4885MAOB 4116/4885CYP19A1 212/4885 |
| US-10696615-B2 | Prenylated hydroxystilbenes | HSD11B1, CYP8B1, NR1H2 | MAOA 3892/4885MAOB 1089/4885CYP19A1 79/4885 |
| US-11352310-B2 | Prenylated hydroxystilbenes | HSD11B1, HSD3B1, CYP8B1 | MAOA 3218/4885MAOB 1156/4885CYP19A1 64/4885 |
| US-20190194105-A1 | PRENYLATED HYDROXYSTILBENES | HSD11B1, CYP8B1, NR1H2 | MAOA 3892/4885MAOB 1089/4885CYP19A1 79/4885 |
| US-11634375-B2 | Prenylated hydroxystilbenes | HCLS1, IWS1, UTS2R | MAOA 4324/4885MAOB 3562/4885CYP19A1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.